Abstract
Every living species has its battle to fight for its existence. While we fight against infectious bacteria, these microorganisms are constantly under attack by their enemy, viruses. In this microscopic warfare, both bacteria and viruses are well-equipped with sophisticated tools against each other. One such tool is CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) which bacteria and archaea use against the virus. CRISPR is a molecular scissor that can selectively attack the genetic material of a virus and cut it into pieces. This damage in the genome does not allow the virus to grow inside bacteria and kill them. The Discovery of CRISPR, out of sheer curiosity, never estimated the development of such promising gene-editing technologies capable of addressing numerous genetic diseases. We will discuss the intriguing story of CRISPR—from its fascinating history to remarkable applications in both basic research and gene therapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Aartsma-Rus A, Janson AAM, Kaman WE et al (2003) Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet 12(8):907–914. https://doi.org/10.1093/hmg/ddg100
Abudayyeh OO, Gootenberg JS, Essletzbichler P et al (2017) RNA targeting with CRISPR-Cas13a. Nature 550(7675):280–284. https://doi.org/10.1038/nature24049
Abudayyeh OO, Gootenberg JS, Franklin B et al (2019) A cytosine deaminase for programmable single-base RNA editing. Science 365(6451):382–386. https://doi.org/10.1126/science.aax7063
Acland GM, Aguirre GD, Ray J et al (2001) Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 28(1):92–95. https://doi.org/10.1038/ng0501-92
Ali Z, Mahas A, Mahfouz M (2018) CRISPR/Cas13 as a tool for RNA interference. Trends Plant Sci 23(5):374–378. https://doi.org/10.1016/j.tplants.2018.03.003
Anders C, Niewoehner O, Duerst A, Jinek M (2014) Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease. Nature 513(7519):569–573. https://doi.org/10.1038/nature13579
Anzalone AV, Randolph PB, Davis JR et al (2019) Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576(7785):149–157. https://doi.org/10.1038/s41586-019-1711-4
Aubrey BJ, Kelly GL, Kueh AJ et al (2015) An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo. Cell Rep 10(8):1422–1432. https://doi.org/10.1016/j.celrep.2015.02.002
Austin DJ, Schreiber SL, Crabtree GR (1994) Proximity versus allostery: the role of regulated protein dimerization in biology. Chem Biol 1(3):131–136. https://doi.org/10.1016/1074-5521(94)90002-7
Bai J, Luo Y, Wang X et al (2020) A protein-independent fluorescent RNA aptamer reporter system for plant genetic engineering. Nat Commun 11(1):3847–3847. https://doi.org/10.1038/s41467-020-17497-7
Barrangou R, Fremaux C, Deveau H et al (2007) CRISPR provides acquired resistance against viruses in prokaryotes. Science 315(5819):1709–1712. https://doi.org/10.1126/science.1138140
Baxter S, Lambert AR, Kuhar R et al (2012) Engineering domain fusion chimeras from I-OnuI family LAGLIDADG homing endonucleases. Nucleic Acids Res 40(16):7985–8000. https://doi.org/10.1093/nar/gks502
Belfort M, Bonocora RP (2014) Homing endonucleases: from genetic anomalies to programmable genomic clippers. Methods Mol Biol 1123:1–26. https://doi.org/10.1007/978-1-62703-968-0_1
Biffi A (2018) Gene therapy as a curative option for β-thalassemia. N Engl J Med 378(16):1551–1552. https://doi.org/10.1056/NEJMe1802169
Bisogno LS, Yang J, Bennett BD et al (2020) Ancestry-dependent gene expression correlates with reprogramming to pluripotency and multiple dynamic biological processes. Sci Adv 6(47):eabc3851. https://doi.org/10.1126/sciadv.abc3851
bluebird bio. A phase 1/2 open label study evaluating the safety and efficacy of gene therapy in subjects with β-thalassemia major by transplantation of autologous CD34+ cells transduced ex vivo with a lentiviral ΒA-T87Q-globin vector (LentiGlobin® BB305 drug product). clinicaltrials.gov; 2019. https://clinicaltrials.gov/ct2/show/NCT01745120. Accessed 22 May 2022.
bluebird bio. A phase 1/2 open label study evaluating the safety and efficacy of gene therapy of the β-hemoglobinopathies (sickle cell anemia and β-thalassemia major) by transplantation of autologous CD34+ stem cells transduced ex vivo with a lentiviral β-A-T87Q globin vector (LentiGlobin BB305 Drug Product). clinicaltrials.gov; 2022. https://clinicaltrials.gov/ct2/show/NCT02151526. Accessed 22 May 2022.
Bolotin A, Quinquis B, Sorokin A, Ehrlich SD (2005) Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. Microbiology 151(8):2551–2561. https://doi.org/10.1099/mic.0.28048-0
Branda CS, Dymecki SM (2004) Talking about a revolution: the impact of site-specific recombinases on genetic analyses in mice. Dev Cell 6(1):7–28. https://doi.org/10.1016/S1534-5807(03)00399-X
Brouns SJJ, Jore MM, Lundgren M et al (2008) Small CRISPR RNAs guide antiviral defense in prokaryotes. Science 321(5891):960–964. https://doi.org/10.1126/science.1159689
Brown W, Zhou W, Deiters A (2021) Regulating CRISPR/Cas9 function through conditional guide RNA control. Chembiochem 22(1):63–72. https://doi.org/10.1002/cbic.202000423
Caine EA, Mahan SD, Johnson RL et al (2020) Targeted protein degradation phenotypic studies using HaloTag CRISPR/Cas9 endogenous tagging coupled with HaloPROTAC3. Curr Protoc Pharmacol 91(1):e81–e81. https://doi.org/10.1002/cpph.81
Cao J, Wu L, Zhang SM et al (2016) An easy and efficient inducible CRISPR/Cas9 platform with improved specificity for multiple gene targeting. Nucleic Acids Res 44(19):e149–e149. https://doi.org/10.1093/nar/gkw660
Carlson-Stevermer J, Abdeen AA, Kohlenberg L et al (2017) Assembly of CRISPR ribonucleoproteins with biotinylated oligonucleotides via an RNA aptamer for precise gene editing. Nat Commun 8(1):1711–1711. https://doi.org/10.1038/s41467-017-01875-9
Cavazzana-Calvo M, Payen E, Negre O et al (2010) Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 467(7313):318–322. https://doi.org/10.1038/nature09328
Chaudhuri A, Halder K, Datta A (2022) Classification of CRISPR/Cas system and its application in tomato breeding. Theor Appl Genet 135(2):367–387. https://doi.org/10.1007/s00122-021-03984-y
Chen B, Huang B (2014) Imaging genomic elements in living cells using CRISPR/Cas9. Methods Enzymol 546:337–354. https://doi.org/10.1016/B978-0-12-801185-0.00016-7
Chien YH, Davidson N (1978) RNA:DNA hybrids are more stable than DNA:DNA duplexes in concentrated perchlorate and trichloroacetate solutions. Nucleic Acids Res 5(5):1627–1637. https://doi.org/10.1093/nar/5.5.1627
Cho S, Yu SI, Park J et al (2017) Accession-dependent CBF gene deletion by CRISPR/Cas system in Arabidopsis. Front Plant Sci 8:1910–1910. https://doi.org/10.3389/fpls.2017.01910
Chylinski K, Le Rhun A, Charpentier E (2013) The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems. RNA Biol 10(5):726–737. https://doi.org/10.4161/rna.24321
Collias D, Beisel CL (2021) CRISPR technologies and the search for the PAM-free nuclease. Nat Commun 12(1):555. https://doi.org/10.1038/s41467-020-20633-y
Cong L, Ran FA, Cox D et al (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339(6121):819–823. https://doi.org/10.1126/science.1231143
Cox DBT, Gootenberg JS, Abudayyeh OO et al (2017) RNA editing with CRISPR-Cas13. Science 358(6366):1019–1027. https://doi.org/10.1126/science.aaq0180
Dagdas YS, Chen JS, Sternberg SH, Doudna JA, Yildiz A (2017) A conformational checkpoint between DNA binding and cleavage by CRISPR-Cas9. Sci Adv 3(8):eaao0027. https://doi.org/10.1126/sciadv.aao0027
Dahlman JE, Abudayyeh OO, Joung J, Gootenberg JS, Zhang F, Konermann S (2015) Orthogonal gene knockout and activation with a catalytically active Cas9 nuclease. Nat Biotechnol 33(11):1159–1161. https://doi.org/10.1038/nbt.3390
Davis KM, Pattanayak V, Thompson DB, Zuris JA, Liu DR (2015) Small molecule–triggered Cas9 protein with improved genome-editing specificity. Nat Chem Biol 11(5):316–318. https://doi.org/10.1038/nchembio.1793
Deltcheva E, Chylinski K, Sharma CM et al (2011) CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471(7340):602–607. https://doi.org/10.1038/nature09886
Demirci S, Leonard A, Tisdale JF (2020) Hematopoietic stem cells from pluripotent stem cells: clinical potential, challenges, and future perspectives. Stem Cells Transl Med 9(12):1549–1557. https://doi.org/10.1002/sctm.20-0247
Dhurandhar D, Sahoo NK, Mariappan I, Narayanan R (2021) Gene therapy in retinal diseases: a review. Indian J Ophthalmol 69(9):2257–2265. https://doi.org/10.4103/ijo.IJO_3117_20
Dzierlega K, Yokota T (2020) Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy. Gene Ther 27(9):407–416. https://doi.org/10.1038/s41434-020-0156-6
Elangkovan N, Dickson G (2021) Gene therapy for Duchenne muscular dystrophy. J Neuromuscul Dis 8(s2):S303–S316. https://doi.org/10.3233/JND-210678
Esvelt KM, Smidler AL, Catteruccia F, Church GM (2014) Concerning RNA-guided gene drives for the alteration of wild populations. eLife 3:e03401. https://doi.org/10.7554/eLife.03401
Fu Y, Sander JD, Reyon D, Cascio VM, Joung JK (2014) Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol 32(3):279–284. https://doi.org/10.1038/nbt.2808
Gaj T, Gersbach CA, Barbas CF (2013) ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 31(7):397–405. https://doi.org/10.1016/j.tibtech.2013.04.004
Gangopadhyay SA, Cox KJ, Manna D et al (2019) Precision control of CRISPR-Cas9 using small molecules and light. Biochemistry 58(4):234–244. https://doi.org/10.1021/acs.biochem.8b01202
Gantz VM, Bier E (2015) The mutagenic chain reaction: a method for converting heterozygous to homozygous mutations. Science 348(6233):442–444. https://doi.org/10.1126/science.aaa5945
Garneau JE, Dupuis MÈ, Villion M et al (2010) The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 468(7320):67–71. https://doi.org/10.1038/nature09523
Garside EL, Schellenberg MJ, Gesner EM et al (2012) Cas5d processes pre-crRNA and is a member of a larger family of CRISPR RNA endonucleases. RNA 18(11):2020–2028. https://doi.org/10.1261/rna.033100.112
Gasiunas G, Barrangou R, Horvath P, Siksnys V (2012) Cas9–crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci U S A 109(39). https://doi.org/10.1073/pnas.1208507109
Gaudelli NM, Komor AC, Rees HA et al (2017) Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature 551(7681):464–471. https://doi.org/10.1038/nature24644
Gaudelli NM, Lam DK, Rees HA et al (2020) Directed evolution of adenine base editors with increased activity and therapeutic application. Nat Biotechnol 38(7):892–900. https://doi.org/10.1038/s41587-020-0491-6
Gilbert LA, Larson MH, Morsut L et al (2013) CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154(2):442–451. https://doi.org/10.1016/j.cell.2013.06.044
Gootenberg JS, Abudayyeh OO, Lee JW et al (2017) Nucleic acid detection with CRISPR-Cas13a/C2c2. Science 356(6336):438–442. https://doi.org/10.1126/science.aam9321
Gootenberg JS, Abudayyeh OO, Kellner MJ, Joung J, Collins JJ, Zhang F (2018) Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science 360(6387):439–444. https://doi.org/10.1126/science.aaq0179
Green AA, Silver PA, Collins JJ, Yin P (2014) Toehold switches: de-novo-designed regulators of gene expression. Cell 159(4):925–939. https://doi.org/10.1016/j.cell.2014.10.002
Groenen PMA, Bunschoten AE, van Soolingen D, van Errtbden JDA. Nature of DNA polymorphism in the direct repeat cluster of Mycobacterium tuberculosis; application for strain differentiation by a novel typing method. Mol Microbiol 1993;10(5):1057–1065. doi:https://doi.org/10.1111/j.1365-2958.1993.tb00976.x
Grünewald J, Zhou R, Lareau CA et al (2020) A dual-deaminase CRISPR base editor enables concurrent adenine and cytosine editing. Nat Biotechnol 38(7):861–864. https://doi.org/10.1038/s41587-020-0535-y
Grunwald HA, Gantz VM, Poplawski G, Xu XRS, Bier E, Cooper KL (2019) Super-Mendelian inheritance mediated by CRISPR–Cas9 in the female mouse germline. Nature 566(7742):105–109. https://doi.org/10.1038/s41586-019-0875-2
Hakim CH, Wasala NB, Pan X et al (2017) A five-repeat micro-dystrophin gene ameliorated dystrophic phenotype in the severe DBA/2J-mdx model of Duchenne muscular dystrophy. Mol Ther Methods Clin Dev 6:216–230. https://doi.org/10.1016/j.omtm.2017.06.006
Hammond A, Pollegioni P, Persampieri T et al (2021) Gene-drive suppression of mosquito populations in large cages as a bridge between lab and field. Nat Commun 12(1):4589. https://doi.org/10.1038/s41467-021-24790-6
Heemskerk H, de Winter CL, van Ommen GJB, van Deutekom JCT, Aartsma-Rus A (2009) Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy. Ann N Y Acad Sci 1175:71–79. https://doi.org/10.1111/j.1749-6632.2009.04973.x
Heler R, Samai P, Modell JW et al (2015) Cas9 specifies functional viral targets during CRISPR–Cas adaptation. Nature 519(7542):199–202. https://doi.org/10.1038/nature14245
Hemphill J, Borchardt EK, Brown K, Asokan A, Deiters A (2015) Optical control of CRISPR/Cas9 gene editing. J Am Chem Soc 137(17):5642–5645. https://doi.org/10.1021/ja512664v
Hendel A, Bak RO, Clark JT et al (2015) Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat Biotechnol 33(9):985–989. https://doi.org/10.1038/nbt.3290
Herold MJ, van den Brandt J, Jost S, Reichardt Holger M (2008) Inducible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in transgenic rats. Proc Natl Acad Sci U S A 105(47):18507–18512. https://doi.org/10.1073/pnas.0806213105
Hirano S, Nishimasu H, Ishitani R, Nureki O (2016) Structural basis for the altered PAM specificities of engineered CRISPR-Cas9. Mol Cell 61(6):886–894. https://doi.org/10.1016/j.molcel.2016.02.018
Hochstrasser ML, Taylor DW, Kornfeld JE, Nogales E, Doudna JA (2016) DNA targeting by a minimal CRISPR RNA-guided cascade. Mol Cell 63(5):840–851. https://doi.org/10.1016/j.molcel.2016.07.027
Hu JH, Miller SM, Geurts MH et al (2018) Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. Nature 556(7699):57–63. https://doi.org/10.1038/nature26155
Hwang WY, Fu Y, Reyon D et al (2013) Heritable and precise zebrafish genome editing using a CRISPR-Cas system. PLoS One 8(7):e68708. https://doi.org/10.1371/journal.pone.0068708
Ishino Y, Shinagawa H, Makino K, Amemura M, Nakata A (1987) Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J Bacteriol 169(12):5429–5433. https://doi.org/10.1128/jb.169.12.5429-5433.1987
Jain PK, Ramanan V, Schepers AG et al (2016) Development of light-activated CRISPR using guide RNAs with photocleavable protectors. Angew Chem Int Ed 55(40):12440–12444. https://doi.org/10.1002/anie.201606123
Jensen TI, Mikkelsen NS, Gao Z et al (2021) Targeted regulation of transcription in primary cells using CRISPRa and CRISPRi. Genome Res 31(11):2120–2130. https://doi.org/10.1101/gr.275607.121
Jeong YK, Lee S, Hwang GH et al (2021) Adenine base editor engineering reduces editing of bystander cytosines. Nat Biotechnol 39(11):1426–1433. https://doi.org/10.1038/s41587-021-00943-2
Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E (2012) A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. Science 337(6096):816–821. https://doi.org/10.1126/science.1225829
Joung JK, Sander JD (2013) TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol 14(1):49–55. https://doi.org/10.1038/nrm3486
Kartje ZJ, Barkau CL, Rohilla KJ, Ageely EA, Gagnon KT (2018) Chimeric guides probe and enhance Cas9 biochemical activity. Biochemistry 57(21):3027–3031. https://doi.org/10.1021/acs.biochem.8b00107
Kearns NA, Pham H, Tabak B et al (2015) Functional annotation of native enhancers with a Cas9-histone demethylase fusion. Nat Methods 12(5):401–403. https://doi.org/10.1038/nmeth.3325
Kell AM, Gale M Jr (2015) RIG-I in RNA virus recognition. Virology 479-480:110–121. https://doi.org/10.1016/j.virol.2015.02.017
Kieper SN, Almendros C, Behler J et al (2018) Cas4 facilitates PAM-compatible spacer selection during CRISPR adaptation. Cell Rep 22(13):3377–3384. https://doi.org/10.1016/j.celrep.2018.02.103
Kim YB, Komor AC, Levy JM, Packer MS, Zhao KT, Liu DR (2017) Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions. Nat Biotechnol 35(4):371–376. https://doi.org/10.1038/nbt.3803
Kim S, Koo T, Jee HG et al (2018) CRISPR RNAs trigger innate immune responses in human cells. Genome Res 28(3):367–373. https://doi.org/10.1101/gr.231936.117
Kleinstiver BP, Prew MS, Tsai SQ et al (2015) Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature 523(7561):481–485. https://doi.org/10.1038/nature14592
Kole R, Krieg AM (2015) Exon skipping therapy for Duchenne muscular dystrophy. Adv Drug Deliv Rev 87:104–107. https://doi.org/10.1016/j.addr.2015.05.008
Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR (2016) Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533(7603):420–424. https://doi.org/10.1038/nature17946
Komor AC, Zhao KT, Packer MS et al (2017) Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity. Sci Adv 3(8):eaao4774. https://doi.org/10.1126/sciadv.aao4774
Konermann S, Brigham MD, Trevino AE et al (2015) Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517(7536):583–588. https://doi.org/10.1038/nature14136
Konermann S, Lotfy P, Brideau NJ, Oki J, Shokhirev MN, Hsu PD (2018) Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors. Cell 173(3):665–676.e14. https://doi.org/10.1016/j.cell.2018.02.033
Koo Y, Ka D, Kim EJ, Suh N, Bae E (2013) Conservation and variability in the structure and function of the Cas5d endoribonuclease in the CRISPR-mediated microbial immune system. J Mol Biol 425(20):3799–3810. https://doi.org/10.1016/j.jmb.2013.02.032
Koonin EV, Makarova KS, Zhang F (2017) Diversity, classification and evolution of CRISPR-Cas systems. Curr Opin Microbiol 37:67–78. https://doi.org/10.1016/j.mib.2017.05.008
Kosicki M, Tomberg K, Bradley A (2018) Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol 36(8):765–771. https://doi.org/10.1038/nbt.4192
Kyrou K, Hammond AM, Galizi R et al (2018) A CRISPR–Cas9 gene drive targeting doublesex causes complete population suppression in caged Anopheles gambiae mosquitoes. Nat Biotechnol 36(11):1062–1066. https://doi.org/10.1038/nbt.4245
Le Guiner C, Servais L, Montus M et al (2017) Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nat Commun 8(1):16105. https://doi.org/10.1038/ncomms16105
Le Rhun A, Escalera-Maurer A, Bratovič M, Charpentier E (2019) CRISPR-Cas in Streptococcus pyogenes. RNA Biol 16(4):380–389. https://doi.org/10.1080/15476286.2019.1582974
Lee K, Mackley VA, Rao A et al (2017) Synthetically modified guide RNA and donor DNA are a versatile platform for CRISPR-Cas9 engineering. elife 6:e25312. https://doi.org/10.7554/eLife.25312
Lee H, Zhou Y, Taylor DW, Sashital DG (2018) Cas4-dependent prespacer processing ensures high-fidelity programming of CRISPR arrays. Mol Cell 70(1):48–59.e5. https://doi.org/10.1016/j.molcel.2018.03.003
Li D, Qiu Z, Shao Y et al (2013) Heritable gene targeting in the mouse and rat using a CRISPR-Cas system. Nat Biotechnol 31(8):681–683. https://doi.org/10.1038/nbt.2661
Li J, Chen Z, Chen F et al (2020) Targeted mRNA demethylation using an engineered dCas13b-ALKBH5 fusion protein. Nucleic Acids Res 48(10):5684–5694. https://doi.org/10.1093/nar/gkaa269
Liang P, Xu Y, Zhang X et al (2015) CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell 6(5):363–372. https://doi.org/10.1007/s13238-015-0153-5
Ling X, Xie B, Gao X et al (2020) Improving the efficiency of precise genome editing with site-specific Cas9-oligonucleotide conjugates. Sci Adv 6(15):eaaz0051. https://doi.org/10.1126/sciadv.aaz0051
Liu KI, Ramli MNB, Woo CWA et al (2016a) A chemical-inducible CRISPR–Cas9 system for rapid control of genome editing. Nat Chem Biol 12(11):980–987. https://doi.org/10.1038/nchembio.2179
Liu XS, Wu H, Ji X et al (2016b) Editing DNA methylation in the mammalian genome. Cell 167(1):233–247.e17. https://doi.org/10.1016/j.cell.2016.08.056
López Del Amo V, Leger BS, Cox KJ et al (2020) Small-molecule control of super-Mendelian inheritance in gene drives. Cell Rep 31(13):107841–107841. https://doi.org/10.1016/j.celrep.2020.107841
Maji B, Moore CL, Zetsche B et al (2017) Multidimensional chemical control of CRISPR–Cas9. Nat Chem Biol 13(1):9–11. https://doi.org/10.1038/nchembio.2224
Maji B, Gangopadhyay SA, Lee M et al (2019) A high-throughput platform to identify small-molecule inhibitors of CRISPR-Cas9. Cell 177(4):1067–1079.e19. https://doi.org/10.1016/j.cell.2019.04.009
Makarova KS, Koonin EV (2015) Annotation and classification of CRISPR-Cas systems. Methods Mol Biol 1311:47–75. https://doi.org/10.1007/978-1-4939-2687-9_4
Makarova KS, Grishin NV, Shabalina SA, Wolf YI, Koonin EV (2006) A putative RNA-interference-based immune system in prokaryotes: computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action. Biol Direct 1(1):7. https://doi.org/10.1186/1745-6150-1-7
Mali P, Yang L, Esvelt KM et al (2013) RNA-guided human genome engineering via Cas9. Science 339(6121):823–826. https://doi.org/10.1126/science.1232033
Mamcarz E, Zhou S, Lockey T et al (2019) Lentiviral gene therapy combined with low-dose Busulfan in infants with SCID-X1. N Engl J Med 380(16):1525–1534. https://doi.org/10.1056/NEJMoa1815408
Manna D, Maji B, Gangopadhyay SA et al (2019) A singular system with precise dosing and spatiotemporal control of CRISPR-Cas9. Angew Chem Int Ed Engl 58(19):6285–6289. https://doi.org/10.1002/anie.201900788
Marraffini LA, Sontheimer EJ (2008) CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA. Science 322(5909):1843–1845. https://doi.org/10.1126/science.1165771
May C, Rivella S, Callegari J et al (2000) Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin. Nature 406(6791):82–86. https://doi.org/10.1038/35017565
McShan WM, Ferretti JJ, Karasawa T et al (2008) Genome sequence of a Nephritogenic and highly transformable M49 strain of Streptococcus pyogenes. J Bacteriol 190(23):7773–7785. https://doi.org/10.1128/JB.00672-08
Melfi R, Cancemi P, Chiavetta R, Barra V, Lentini L, Di Leonardo A (2020) Investigating REPAIRv2 as a tool to edit CFTR mRNA with premature stop codons. Int J Mol Sci 21(13):E4781. https://doi.org/10.3390/ijms21134781
Metzger D, Clifford J, Chiba H, Chambon P (1995) Conditional site-specific recombination in mammalian cells using a ligand-dependent chimeric Cre recombinase. Proc Natl Acad Sci U S A 92(15):6991–6995. https://doi.org/10.1073/pnas.92.15.6991
Mir A, Alterman JF, Hassler MR et al (2018) Heavily and fully modified RNAs guide efficient SpyCas9-mediated genome editing. Nat Commun 9(1):2641–2641. https://doi.org/10.1038/s41467-018-05073-z
Miyagi A, Lu A, Humphreys BD (2016) Gene editing: powerful new tools for nephrology research and therapy. J Am Soc Nephrol 27(10):2940–2947. https://doi.org/10.1681/ASN.2016020146
Mojica FJM, Juez G, Rodriguez-Valera F (1993) Transcription at different salinities of Haloferax mediterranei sequences adjacent to partially modified PstI sites. Mol Microbiol 9(3):613–621. https://doi.org/10.1111/j.1365-2958.1993.tb01721.x
Mojica FJM, Díez-Villaseñor C, García-Martínez J, Soria E (2005) Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J Mol Evol 60(2):174–182. https://doi.org/10.1007/s00239-004-0046-3
Moore M, Klug A, Choo Y (2001) Improved DNA binding specificity from polyzinc finger peptides by using strings of two-finger units. Proc Natl Acad Sci 98(4):1437–1441. https://doi.org/10.1073/pnas.98.4.1437
Moroz-Omori EV, Satyapertiwi D, Ramel MC et al (2020) Photoswitchable gRNAs for spatiotemporally Controlled CRISPR-Cas-based genomic regulation. ACS Cent Sci 6(5):695–703. https://doi.org/10.1021/acscentsci.9b01093
Myhrvold C, Freije CA, Gootenberg JS et al (2018) Field-deployable viral diagnostics using CRISPR-Cas13. Science 360(6387):444–448. https://doi.org/10.1126/science.aas8836
Nam KH, Haitjema C, Liu X et al (2012) Cas5d protein processes pre-crRNA and assembles into a cascade-like interference complex in subtype I-C/Dvulg CRISPR-Cas system. Structure 20(9):1574–1584. https://doi.org/10.1016/j.str.2012.06.016
Naranjo S, Smith JD, Artieri CG et al (2015) Dissecting the genetic basis of a complex cis-regulatory adaptation. PLoS Genet 11(12):e1005751–e1005751. https://doi.org/10.1371/journal.pgen.1005751
Nash BM, Wright DC, Grigg JR, Bennetts B, Jamieson RV (2015) Retinal dystrophies, genomic applications in diagnosis and prospects for therapy. Transl Pediatr 4(2):139–163. https://doi.org/10.3978/j.issn.2224-4336.2015.04.03
Nelles DA, Fang MY, O’Connell MR et al (2016) Programmable RNA tracking in live cells with CRISPR/Cas9. Cell 165(2):488–496. https://doi.org/10.1016/j.cell.2016.02.054
Nelson JW, Randolph PB, Shen SP et al (2022) Engineered pegRNAs improve prime editing efficiency. Nat Biotechnol 40(3):402–410. https://doi.org/10.1038/s41587-021-01039-7
Nihongaki Y, Yamamoto S, Kawano F, Suzuki H, Sato M (2015) CRISPR-Cas9-based photoactivatable transcription system. Chem Biol 22(2):169–174. https://doi.org/10.1016/j.chembiol.2014.12.011
Niu Y, Shen B, Cui Y et al (2014) Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell 156(4):836–843. https://doi.org/10.1016/j.cell.2014.01.027
NS Pharma, Inc. A phase II, dose finding study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of NS-065/NCNP-01 in boys with Duchenne muscular dystrophy (DMD). clinicaltrials.gov; 2021. https://clinicaltrials.gov/ct2/show/NCT02740972. Accessed 19 May 2022.
Nussenzweig PM, Marraffini LA (2020) Molecular mechanisms of CRISPR-Cas immunity in bacteria. Annu Rev Genet 54(1):93–120. https://doi.org/10.1146/annurev-genet-022120-112523
O’Connell MR (2019) Molecular mechanisms of RNA targeting by Cas13-containing type VI CRISPR-Cas systems. J Mol Biol 431(1):66–87. https://doi.org/10.1016/j.jmb.2018.06.029
Oakes BL, Fellmann C, Rishi H et al (2019) CRISPR-Cas9 circular permutants as programmable scaffolds for genome modification. Cell 176(1–2):254–267.e16. https://doi.org/10.1016/j.cell.2018.11.052
Oldrini B, Curiel-García Á, Marques C et al (2018) Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling. Nat Commun 9(1):1466. https://doi.org/10.1038/s41467-018-03731-w
Pawliuk R, Westerman KA, Fabry ME et al (2001) Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 294(5550):2368–2371. https://doi.org/10.1126/science.1065806
Pfizer. A Phase 3, multicenter, randomized, double-blind, placebo controlled study to evaluate the safety and efficacy of PF 06939926 for the treatment of Duchenne muscular dystrophy. clinicaltrials.gov; 2022. https://clinicaltrials.gov/ct2/show/NCT04281485. Accessed 19 May 2022.
Porto EM, Komor AC, Slaymaker IM, Yeo GW (2020) Base editing: advances and therapeutic opportunities. Nat Rev Drug Discov 19(12):839–859. https://doi.org/10.1038/s41573-020-0084-6
Pourcel C, Salvignol G, Vergnaud G (2005) CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies. Microbiology 151(3):653–663. https://doi.org/10.1099/mic.0.27437-0
Pruett-Miller SM, Reading DW, Porter SN, Porteus MH (2009) Attenuation of zinc finger nuclease toxicity by small-molecule regulation of protein levels. PLoS Genet 5(2):e1000376. https://doi.org/10.1371/journal.pgen.1000376
Qi LS, Larson MH, Gilbert LA et al (2013) Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152(5):1173–1183. https://doi.org/10.1016/j.cell.2013.02.022
Rakhit R, Navarro R, Wandless TJ (2014) Chemical biology strategies for posttranslational control of protein function. Chem Biol 21(9):1238–1252
Ran FA, Hsu PD, Lin CY et al (2013) Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154(6):1380–1389. https://doi.org/10.1016/j.cell.2013.08.021
Rao C, Guyard C, Pelaz C et al (2016) Active and adaptive Legionella CRISPR-Cas reveals a recurrent challenge to the pathogen. Cell Microbiol 18(10):1319–1338. https://doi.org/10.1111/cmi.12586
Rao C, Chin D, Ensminger AW (2017) Priming in a permissive type I-C CRISPR–Cas system reveals distinct dynamics of spacer acquisition and loss. RNA 23(10):1525–1538. https://doi.org/10.1261/rna.062083.117
Reeks J, Naismith JH, White MF (2013) CRISPR interference: a structural perspective. Biochem J 453(2):155–166. https://doi.org/10.1042/BJ20130316
Richter MF, Zhao KT, Eton E et al (2020) Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity. Nat Biotechnol 38(7):883–891. https://doi.org/10.1038/s41587-020-0453-z
Rivella S, May C, Chadburn A, Rivière I, Sadelain M (2003) A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human β-globin gene transfer. Blood 101(8):2932–2939. https://doi.org/10.1182/blood-2002-10-3305
Rollie C, Graham S, Rouillon C, White MF (2018) Prespacer processing and specific integration in a type I-A CRISPR system. Nucleic Acids Res 46(3):1007–1020. https://doi.org/10.1093/nar/gkx1232
Sarepta Therapeutics, Inc. Clinical study to assess the safety Fo AVI-4658 in subjects with Duchenne muscular dystrophy due to a frame-shift mutation amenable to correction by skipping exon 51. clinicaltrials.gov; 2015. https://clinicaltrials.gov/ct2/show/NCT00844597. Accessed 19 May 2022.
Sarepta Therapeutics, Inc. A randomized, double-blind, placebo-controlled, multiple dose efficacy, safety, tolerability and pharmacokinetics study of AVI-4658(Eteplirsen), in the treatment of ambulant subjects with duchenne muscular dystrophy. clinicaltrials.gov; 2020a. https://clinicaltrials.gov/ct2/show/NCT01396239. Accessed 19 May 2022.
Sarepta Therapeutics, Inc. A 2-part, randomized, double-blind, placebo-controlled, dose-titration, safety, tolerability, and pharmacokinetics study (part 1) followed by an open-label efficacy and safety evaluation (part 2) of SRP-4053 in patients with Duchenne muscular dystrophy amenable to exon 53 skipping. clinicaltrials.gov; 2020b. https://clinicaltrials.gov/ct2/show/NCT02310906. Accessed 19 May 2022.
Sarepta Therapeutics, Inc. A multicenter, randomized, double-blind, placebo-controlled trial for Duchenne muscular dystrophy using SRP-9001. clinicaltrials.gov; 2021. https://clinicaltrials.gov/ct2/show/NCT03769116. Accessed 19 May 2022.
Sarepta Therapeutics, Inc. Systemic gene delivery phase I/IIa clinical trial for Duchenne muscular dystrophy using RAAVrh74.MHCK7.Micro-Dystrophin (MicroDys-IV-001). clinicaltrials.gov; 2022a. https://clinicaltrials.gov/ct2/show/NCT03375164. Accessed 19 May 2022.
Sarepta Therapeutics, Inc. A double-blind, placebo-controlled, multi-center study with an open-label extension to evaluate the efficacy and safety of SRP-4045 and SRP-4053 in patients with Duchenne muscular dystrophy. clinicaltrials.gov; 2022b. https://clinicaltrials.gov/ct2/show/NCT02500381. Accessed 19 May 2022.
Savic N, Ringnalda FC, Lindsay H et al (2018) Covalent linkage of the DNA repair template to the CRISPR-Cas9 nuclease enhances homology-directed repair. elife 7:e33761. https://doi.org/10.7554/eLife.33761
Schierling B, Dannemann N, Gabsalilow L, Wende W, Cathomen T, Pingoud A (2012) A novel zinc-finger nuclease platform with a sequence-specific cleavage module. Nucleic Acids Res 40(6):2623–2638. https://doi.org/10.1093/nar/gkr1112
Schubert MS, Cedrone E, Neun B, Behlke MA, Dobrovolskaia MA (2018) Chemical modification of CRISPR gRNAs eliminate type I interferon responses in human peripheral blood mononuclear cells. J Cytokine Biol 3(1):121. https://doi.org/10.4172/2576-3881.1000121
Senturk S, Shirole NH, Nowak DG et al (2017) Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization. Nat Commun 8:14370–14370. https://doi.org/10.1038/ncomms14370
Shakirova KM, Ovchinnikova VY, Dashinimaev EB (2020) Cell reprogramming with CRISPR/Cas9 based transcriptional regulation systems. Front Bioeng Biotechnol 8:882–882. https://doi.org/10.3389/fbioe.2020.00882
Shin HY, Wang C, Lee HK et al (2017) CRISPR/Cas9 targeting events cause complex deletions and insertions at 17 sites in the mouse genome. Nat Commun 8(1):15464. https://doi.org/10.1038/ncomms15464
Shmakov S, Abudayyeh OO, Makarova KS et al (2015) Discovery and functional characterization of diverse class 2 CRISPR-Cas systems. Mol Cell 60(3):385–397. https://doi.org/10.1016/j.molcel.2015.10.008
Shrimp JH, Grose C, Widmeyer SRT, Thorpe AL, Jadhav A, Meier JL (2018) Chemical control of a CRISPR-Cas9 acetyltransferase. ACS Chem Biol 13(2):455–460. https://doi.org/10.1021/acschembio.7b00883
Silva G, Poirot L, Galetto R et al (2011) Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy. Curr Gene Ther 11(1):11–27. https://doi.org/10.2174/156652311794520111
Siu KH, Chen W (2019) Riboregulated toehold-gated gRNA for programmable CRISPR–Cas9 function. Nat Chem Biol 15(3):217–220. https://doi.org/10.1038/s41589-018-0186-1
Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F (2016) Rationally engineered Cas9 nucleases with improved specificity. Science 351(6268):84–88. https://doi.org/10.1126/science.aad5227
Smith J (2000) Requirements for double-strand cleavage by chimeric restriction enzymes with zinc finger DNA-recognition domains. Nucleic Acids Res 28(17):3361–3369. https://doi.org/10.1093/nar/28.17.3361
Solid Biosciences, LLC. A randomized, controlled, open-label, single-ascending dose, phase I/II study to investigate the safety and tolerability, and efficacy of intravenous SGT-001 in male adolescents and children with Duchenne muscular dystrophy. clinicaltrials.gov; 2022. https://clinicaltrialsgov/ct2/show/NCT03368742. Accessed 19 May 2022.
Spark Therapeutics. A safety and efficacy study in subjects with Leber congenital amaurosis (LCA) using adeno-associated viral vector to deliver the gene for human RPE65 to the retinal pigment epithelium (RPE) [AAV2-HRPE65v2-301]. clinicaltrials.gov; 2021. https://clinicaltrials.gov/ct2/show/NCT00999609. Accessed 19 May 2022.
Sreekanth V, Zhou Q, Kokkonda P et al (2020) Chemogenetic system demonstrates that Cas9 longevity impacts genome editing outcomes. ACS Cent Sci 6(12):2228–2237. https://doi.org/10.1021/acscentsci.0c00129
Stadtmauer EA, Fraietta JA, Davis MM et al (2020) CRISPR-engineered T cells in patients with refractory cancer. Science 367(6481):eaba7365. https://doi.org/10.1126/science.aba7365
Stafforst T, Schneider MF (2012) An RNA-deaminase conjugate selectively repairs point mutations. Angew Chem Int Ed Engl 51(44):11166–11169. https://doi.org/10.1002/anie.201206489
Stefanie U, Udo B, Marion T, Hasan MT, Hermann B, Wolfgang H (2000) Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci U S A 97(14):7963–7968. https://doi.org/10.1073/pnas.130192197
Sternberg SH, LaFrance B, Kaplan M, Doudna JA (2015) Conformational control of DNA target cleavage by CRISPR-Cas9. Nature 527(7576):110–113. https://doi.org/10.1038/nature15544
Stoddard BL (2006) Homing endonuclease structure and function. Q Rev Biophys 38(01):49. https://doi.org/10.1017/S0033583505004063
Stoddard BL (2014) Homing endonucleases from mobile group I introns: discovery to genome engineering. Mob DNA 5(1):7. https://doi.org/10.1186/1759-8753-5-7
Szczelkun MD, Tikhomirova MS, Sinkunas T et al (2014) Direct observation of R-loop formation by single RNA-guided Cas9 and Cascade effector complexes. Proc Natl Acad Sci U S A 111(27):9798–9803. https://doi.org/10.1073/pnas.1402597111
Tak YE, Kleinstiver BP, Nuñez JK et al (2017) Inducible and multiplex gene regulation using CRISPR–Cpf1-based transcription factors. Nat Methods 14(12):1163–1166. https://doi.org/10.1038/nmeth.4483
Takeuchi N, Wolf YI, Makarova KS, Koonin EV (2012) Nature and intensity of selection pressure on CRISPR-associated genes. J Bacteriol 194(5):1216–1225. https://doi.org/10.1128/JB.06521-11
Tanenbaum ME, Gilbert LA, Qi LS, Weissman JS, Vale RD (2014) A protein-tagging system for signal amplification in gene expression and fluorescence imaging. Cell 159(3):635–646. https://doi.org/10.1016/j.cell.2014.09.039
Tang W, Hu JH, Liu DR (2017) Aptazyme-embedded guide RNAs enable ligand-responsive genome editing and transcriptional activation. Nat Commun 8:15939–15939. https://doi.org/10.1038/ncomms15939
Tang T, Han Y, Wang Y, Huang H, Qian P (2021) Programmable system of Cas13-mediated RNA modification and its biological and biomedical applications. Front Cell Dev Biol 9:677587. https://doi.org/10.3389/fcell.2021.677587
Taylor GK, Petrucci LH, Lambert AR, Baxter SK, Jarjour J, Stoddard BL (2012) LAHEDES: the LAGLIDADG homing endonuclease database and engineering server. Nucleic Acids Res 40(W1):W110–W116. https://doi.org/10.1093/nar/gks365
Tsai SQ, Wyvekens N, Khayter C et al (2014) Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat Biotechnol 32(6):569–576. https://doi.org/10.1038/nbt.2908
van Deutekom JCT, van Ommen GJB (2003) Advances in Duchenne muscular dystrophy gene therapy. Nat Rev Genet 4(10):774–783. https://doi.org/10.1038/nrg1180
Vojta A, Dobrinić P, Tadić V et al (2016) Repurposing the CRISPR-Cas9 system for targeted DNA methylation. Nucleic Acids Res 44(12):5615–5628. https://doi.org/10.1093/nar/gkw159
Wan W, Tharp JM, Liu WR (2014) Pyrrolysyl-tRNA synthetase: an ordinary enzyme but an outstanding genetic code expansion tool. Biochim Biophys Acta 1844(6):1059–1070. https://doi.org/10.1016/j.bbapap.2014.03.002
Wang H, Yang H, Shivalila CS et al (2013) One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153(4):910–918. https://doi.org/10.1016/j.cell.2013.04.025
Wang L, Li F, Dang L et al (2016) In vivo delivery systems for therapeutic genome editing. Int J Mol Sci 17(5):626. https://doi.org/10.3390/ijms17050626
Wang S, Wei L, Wang JQ et al (2020) Light-driven activation of RNA-guided nucleic acid cleavage. ACS Chem Biol 15(6):1455–1463. https://doi.org/10.1021/acschembio.0c00105
Wang J, Teng Y, Zhang R et al (2021) Engineering a PAM-flexible SpdCas9 variant as a universal gene repressor. Nat Commun 12(1):6916–6916. https://doi.org/10.1038/s41467-021-27290-9
Wei Y, Terns RM, Terns MP (2015) Cas9 function and host genome sampling in type II-A CRISPR–Cas adaptation. Genes Dev 29(4):356–361. https://doi.org/10.1101/gad.257550.114
Wienert B, Shin J, Zelin E, Pestal K, Corn JE (2018) In vitro-transcribed guide RNAs trigger an innate immune response via the RIG-I pathway. PLoS Biol 16(7):e2005840. https://doi.org/10.1371/journal.pbio.2005840
Wilson C, Chen PJ, Miao Z, Liu DR (2020) Programmable m6A modification of cellular RNAs with a Cas13-directed methyltransferase. Nat Biotechnol 38(12):1431–1440. https://doi.org/10.1038/s41587-020-0572-6
Xu C, Zhou Y, Xiao Q et al (2021) Programmable RNA editing with compact CRISPR-Cas13 systems from uncultivated microbes. Nat Methods 18(5):499–506. https://doi.org/10.1038/s41592-021-01124-4
Yan WX, Chong S, Zhang H et al (2018) Cas13d is a compact RNA-targeting type VI CRISPR effector positively modulated by a WYL domain-containing accessory protein. Mol Cell 70(2):327–339.e5. https://doi.org/10.1016/j.molcel.2018.02.028
Yin H, Song CQ, Suresh S et al (2018) Partial DNA-guided Cas9 enables genome editing with reduced off-target activity. Nat Chem Biol 14(3):311–316. https://doi.org/10.1038/nchembio.2559
Yokota T, Duddy W, Partridge T (2007) Optimizing exon skipping therapies for DMD. Acta Myol 26(3):179–184
Yu Y, Wu X, Guan N et al (2020) Engineering a far-red light-activated split-Cas9 system for remote-controlled genome editing of internal organs and tumors. Sci Adv 6(28):eabb1777. https://doi.org/10.1126/sciadv.abb1777
Zetsche B, Volz SE, Zhang F (2015) A split-Cas9 architecture for inducible genome editing and transcription modulation. Nat Biotechnol 33(2):139–142. https://doi.org/10.1038/nbt.3149
Zhang L, Jia R, Palange NJ et al (2015) Large genomic fragment deletions and insertions in mouse using CRISPR/Cas9. PLoS One 10(3):e0120396. https://doi.org/10.1371/journal.pone.0120396
Zhang J, Chen L, Zhang J, Wang Y (2019) Drug inducible CRISPR/Cas systems. Comput Struct Biotechnol 17:1171–1177. https://doi.org/10.1016/j.csbj.2019.07.015
Zhang X, Zhu B, Chen L et al (2020a) Dual base editor catalyzes both cytosine and adenine base conversions in human cells. Nat Biotechnol 38(7):856–860. https://doi.org/10.1038/s41587-020-0527-y
Zhang Y, Ling X, Su X et al (2020b) Optical control of a CRISPR/Cas9 system for gene editing by using Photolabile crRNA. Angew Chem 132(47):21081–21085
Zhao J, Li B, Ma J, Jin W, Ma X (2020) Photoactivatable RNA N6 -Methyladenosine editing with CRISPR-Cas13. Small 16(30):e1907301. https://doi.org/10.1002/smll.201907301
Zhou X, Vink M, Klaver B, Berkhout B, Das AT (2006) Optimization of the Tet-on system for regulated gene expression through viral evolution. Gene Ther 13(19):1382–1390. https://doi.org/10.1038/sj.gt.3302780
Zhou W, Brown W, Bardhan A et al (2020) Spatiotemporal control of CRISPR/Cas9 function in cells and zebrafish using light-activated guide RNA. Angew Chem 59(23):8998–9003. https://doi.org/10.1002/anie.201914575
Acknowledgements
We greatly acknowledge Dr. Donghyun Lim (Sungshin University) for useful discussions and comments. We thank ArtiVerse for their input in the graphics. We thank Ramalingaswami Fellowship BT/RLF/Re-entry/58/2020 (to BM), SERB SRG/2021/001713 (to BM), Ashoka University, and Bose Institute for the financial support.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Mistry, A., Tanga, S., Maji, B. (2023). Nucleic Acid Editing. In: Chatterjee, S., Chattopadhyay, S. (eds) Nucleic Acid Biology and its Application in Human Diseases. Springer, Singapore. https://doi.org/10.1007/978-981-19-8520-1_11
Download citation
DOI: https://doi.org/10.1007/978-981-19-8520-1_11
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-19-8519-5
Online ISBN: 978-981-19-8520-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)